EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) | MicrobiomeTrials← Back to trialsNCT07047703
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-07-28Est. Completion: 2028-04-30
Enrollment target: 141 participants Locations- University of the Sunshine Coast (UniSC), Birtinya, Australia
- University of the Sunshine Coast (UniSC), Morayfield, Australia
- The Colin Bayliss Research and Teaching Unit, Perth, Australia
- Pioneer Clinical Research, Sydney, Australia
- University Ghent, Ghent, Belgium
- UZ Leuven, Leuven, Belgium
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany
- Universitätsklinikum Erlangen - Medizinische Klinik 3, Erlangen, Germany
- Amsterdam University Medical Center, Amsterdam, Netherlands
- Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center), Leiden, Netherlands
- Malopolskie Badania Kliniczne (MBK Clinic), Krakow, Małopolska, Poland
- ETG Lublin, Lublin, Poland
- Reumedika, Poznan, Poland
- La Paz University Hospital, Madrid, Fuencarral-El Pardo, Spain
- Reina Sofia University Hospital, Córdoba, Poniente Sur, Spain
- University hospital Parc Tauli de Sabadell, Sabadell, Spain
Other microbiome trials you might be interested in
Axial Spondyloarthritis (AxSpA)Spondyloarthritis (SpA)Chronic Back Pain
This study aims to validate the 2025 ASAS-SPARTAN revised classification criteria for axial spondyloarthritis (axSpA) in…
Beijing, ChinaEst. completion Apr 10, 2027
Non-radiographic Axial Spondyloarthritis
The purpose of this study is to evaluate preliminary efficacy, safety pharmacokinetic (PK) characteristics, pharmacodyna…
Hefei, ChinaCompleted Mar 13, 2023